Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Humphreys, Eliza H ^a   Hernandez, L B ^b   Rutherford, G W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Anti HIV agents *therapeutic use ; Drug therapy, combination; HIV infections *drug therapy ; Humans; Reverse transcriptase inhibitors *therapeutic use ; Treatment failure

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 44949158909     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006517.pub2     Document Type: Review

References (62)

1. Albrecht 1999 Albrecht M, Katzenstein D, Hammer S. The Effectiveness of Nelfinavir and Efavirenz, used alone or together, combined with other anti-HIV drugs in patients who have taken anti-HIV drugs. 1999 Nov; Vol. ACTG 364:NCT00001087.
2. Bartlett 2003 Bartlett JA, Tebas P, Bassett R, et al.Early intensification with abacavir in subjects at high risk for incomplete viral suppression. Antivir Ther 2003 Aug;8(4):361-3.
3. Durant 1999 Durant J, Clevenbergh P, Halfon P, et al.Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999 Jun;353(9171):2195-9.
4. Fethi 2005 Fethi T, Asma J, Amine SM, et al.Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings. Curr HIV Res 2005 Jul;3(3):271-6.
5. Fischl 2005 Fischl M, Bassett R, Collier A, et al.Randomized, Controlled Clinical Trial of Lopinavir/Ritonavir + Efavirenz vs Efavirenz + 2 nucleoside reverse transcriptase inhibitors following a first suppressive 3- or 4-drug regimen in advanced HIV disease. Conf Retrovir Opportunistic Infect. 2005 Feb 22-2; Vol. 12:abstract no. 162.
6. Gianotti 2006 Gianotti N, Mondino V, Rossi MC, et al.Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. Clin Infect Dis 2006 May;42(10):1470-80.
7. Hammer 1999 Hammer S. Treatment success and failure in HIV-infected subjects receiving Indinavir in combination with nucleoside analogs: a rollover study for ACTG320. 1999Nov;ACTG 372, 701, 702, 706: NCT00000885.
8. Lamarca 2006 Lamarca A, Clumeck N, Plettenberg A, et al.Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1 infected patients (CAL30001 Study). J Acquir Immune Defic Syndr 2006 Apr;41(5):598-606.
9. Maggiolo 2003 Maggiolo F, Callegaro A, Arici C, et al.Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. Antiv Ther 2003 Apr;8(2):121-6.
10. Martin 2004 Martin-Carbonero L, Barrios A, Saballs A, et al.Pegylated liposomal doxorubicin plus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004 Aug;18(12):1737-40.
11. Phillips 2004 Phillips AN, Ledergerber B, Horban A, et al.Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004 Sep;18(13):1795-804.
12. Robbins 2003 Robbins GK, De Gruttola V, Shafer RW, et al.Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 Dec;349(24):2293-303.
13. Shafer 2003 Shafer RW, Smeaton LM, Robbins GK, et al.Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 Dec;349(24):2304- 15.
14. Smeaton 2001 Smeaton LM, DeGruttols V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trial Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials 2001 Apr;22(2):142-59.
15. Tural 2002 Tural C, Ruiz L, Holtzer C, et al.Clinical Utility of HIV-1 genotyping and expert Advice: the Havana trial. AIDS 2002 Jan;16(2):209-218.
16. Arnsten 2001 Arnsten JH, Demas PA, Farzadegan H, et al.Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001 Oct;33:1417-23.
17. Beck 2006 Beck E, Vitoria JM, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?. AIDS 2006 Jul;20(11):1497-502.
18. Brenner 2002 Brenner BG, Routy JP, Petrella M, et al.Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002 Feb;76(4):1753-61.
19. Carr 2000 Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000 Oct;356(9239):1423-30.
20. Cattelan 1999 Cattelan AM, Erne E, Salatino A, et al.Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999 Aug;29(2):455-6.
21. Chersich 2006 Chersich MF, Urban MF, Venter FW, et al.Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006 Apr;3:11.
22. Chou 2006 Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006 Oct;368:1503-15.
23. Cingolani 2002 Cingolani A, Antinori A, Rizzo MG, et al.Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a Randomized study (ARGENTA). AIDS 2002 Feb;16(3):369-379.
24. Darbyshire 2000 Darbyshire J, Foulkes M, Peto R, et al.Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database of Systematic Reviews 2000, Issue 3.Art. No.: CD002038. DOI:10.1002/14651858.CD002038.
25. Deeks 2001 Deeks SG, Wrin T, Liegler T, et al.Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001 Feb;344(7):472-80.
26. Fatkenheuer 1997 Fatkenheuer G, Theisen A, Rockstroh J, et al.Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997 Nov;11(14):F113-6.
27. FDA 2006 Food, Drug Administration. Retrovir Prescribing Information 2006. Available at: http://www.fda.gov/cder/foi/label/2006/ 019655s043lbl.pdf. Accessed August 21, 2007.
28. Gallant 2007 Gallant JE. Drug Resistance after Failure of Initial Antiretroviral Therapy in Resource-Limited Countries. Clin Infect Dis 2007 Feb; 44(3):453-5.
29. Gilks 2006 Gilks CF, Crowley S, Ekpini R, et al.The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006 Aug;368(9534):505-10.
30. Grant 2002 Grant RM, Hecht FM, Warmerdam M, et al.Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002 Jul;288(2):181-8.
31. Hammer 2006 Hammer SM, Saag MS, Schechter M, et al.Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 2006 Aug;296(7):827-843.
32. Harris 2000 Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol 2000 Jul-Aug;10(4):217-29.
33. Hartmann 2001 Hartmann M, Rump A, Brust J, et al.Evaluation of an efavirenz-containing regimen: an open-label, multicenter study. HIV Clin Trials 2001 Sep-Oct;2(5):421-8.
34. Hirsch 2003 Hirsch MS, Brun-Vezinet F, Clotet B, et al.Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003 Jul;37(1):113-28.
35. Holtgrave 2005 Holtgrave DR. Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?. Int J STD AIDS 2005; 16(12):777-81.
36. Jeantils 2006 Jeantils V, Khuong MA, Delassus JL, et al.Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients. Gynecol Obstet Fertil 2006 Jul-Aug;34(7-8):593-6.
37. Katzenstein 1996 Katzenstein DA, Hammer SM, Hughes MD, et al.The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996 Oct;335(15):1091-8.
38. Kumarasamy 2006 Kumarasamy N, Bartlett J. Safety and effectiveness of Lopinavir/Ritonavir in individuals who have failed prior HIV therapy. 2006 Jul;ACTG A5230:NCT00357552.
39. Ledergerber 1999 Ledergerber B, Egger M, Opravil M, et al.Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999 Mar;353(9156):863-8.
40. Manfredi 2002 Manfredi R, Calza L, Chiodo F. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. J Antimicrob Chemother 2002 May;49(5):723-9.
41. Marschner 1998 Marschner IC, Collier AC, Coombs RW. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998 Jan;177(1):40-7.
42. Mellors 1996 Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996 May;272(5265):1167-70.
43. Miller 2000 Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Read 2000 Mar;10(3):177-85.
44. MOH Uganda 2003 Ministry of Health, Republic of Uganda. National Antiretroviral Treatment and Care Guidelines for Adults and Children, 1st Edition. November 2003:Available at: http://hivinsite.ucsf.edu/doc/cr09-ug- ARVguidelines.
45. Moyle 2000 Moyle G. Clinical Manifestations and Management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000 Aug;22(8):911-36.
46. Palella 1998 Palella FJ Jr, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 Mar;338(13):853-60.
47. Parienti 2004 Parienti JJ, Massari V, Descamps D. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004 May;38(9):1311-6.
48. Phillips 2002 Phillips EJ, Kuriakose B, Knowles SR. Efavirenz-induced skin eruption and successful desensitization. Ann Pharmacother 2002 Mar;36(3):430-2.
49. Pillay 2000 Pillay D, Cane PA, Shirley J, Porter K. Detection of drug resistance associatedmutations in HIV primary infection within the UK. AIDS 2000 May;14(7):906-8.
50. Podzamczer 2001 Podzamczer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Expert Opin Pharmacother 2001 Dec;2(12):2065-78.
51. Pulido 2004 Pulido F, Arribas JR, Miro JM, et al.Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004 Apr;35(4):343-50.
52. Rutherford 2003 Rutherford GW, Sangani PR, Kennedy, GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database of Systematic Reviews Issue 4.Art.No.:CD002037. DOI:10.1002/14651858.CD002037.
53. Shibuyama 2006 Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006;12(9):1075-90.
54. Sidley 2000 Sidley P. South Africa to tighten control on drug trials after five deaths. BMJ 2000 Apr;320(7241):1028.
55. Staszewski 1999 Staszewski S, Morales-Ramirez J, Tashima KT, et al.Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999 Dec;341(25):1865-73.
56. Stern 2003 Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003 Sep;34 Suppl 1:S21-33.
57. Sungkanuparph 2007 Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al.Options for a Second-Line Antiretroviral Regimen for HIV Type 1-Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine Fails. Clin Infect Dis 2007 Feb;44(3):447-52.
58. US DHHS 2006 US DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS Panel on Antiretroviral Agents in Adults and adolescents - A Working Group of the Office of AIDS Research and Advisory Council (OARAC). October 2006:Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.
59. van Leth 2004 van Leth F, Phanuphak P, Ruxrungtham K, et al.Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004 Apr;363 (9417):1253-63.
60. Wells GA Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottowa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine. Available at: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.
61. Wensing 2005 Wensing AMJ, van de Vijver DA, Angarano G, et al.Prevalence of drug resistant HIV-1 variants in un-treated individuals in Europe: implications for clinical management. J Infect Dis 2005 Sep;192(6):958-66.
62. WHO 2006 World Health Organization. Antiretroviral therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public health Approach. 2006 Revision:Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.